Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


I need to know
Feb 28, 2008

I am now taking Viramune, Epivir and Zerit. What I would like to know is can I switch the Zerit for Kaletra. Thank you Stan.

Response from Dr. Young

Stan, Thank you for your post.

While you could switch from d4T (Zerit) to lopinavir/ritonavir (Kaletra), I'm not sure why anyone would even entertain this.

From the sounds of it, you're taking a first-line regimen. It would be reasonable to consider eliminating the toxic and now-not-recommended d4T, but contemporary treatments could include your current nevirapine (Viramune) and 3TC (Epivir) with either tenofovir (Viread or in combination with FTC in Truvada) or abacavir (Zigen, also combined in Epzicom). Such regimens would be consistent with current US and international treatment guidelines.

I hope that you find this helpful. BY



Previous
strange phenomenon
Next
Aids cure

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement